Quick Answer
IGC Pharma, Inc. reported Gross Profit of $619.0 thousand for the year ending 2025.
- IGC Pharma, Inc. showed a decrease of -15.6% in Gross Profit from 2024 to 2025.
- This data is from IGC Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on June 27, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: $39.0 thousand | Q2 2018: $42.0 thousand | Q3 2018: $18.0 thousand | Q4 2018: $45.0 thousand | Q2 2019: $41.0 thousand | Q3 2019: $28.0 thousand | Q4 2019: $30.0 thousand | Q2 2020: $46.0 thousand | Q3 2020: $26.0 thousand | Q4 2020: $14.0 thousand | Q2 2021: $26.0 thousand | Q3 2021: $38.0 thousand | Q4 2021: $62.0 thousand | Q2 2022: $142.0 thousand | Q3 2022: $135.0 thousand | Q4 2022: $102.0 thousand | Q2 2023: $255.0 thousand | Q3 2023: $174.0 thousand | Q4 2023: $133.0 thousand | Q2 2024: $163.0 thousand | Q3 2024: $198.0 thousand | Q4 2024: $104.0 thousand | Q2 2025: $154.0 thousand | Q3 2025: $99.0 thousand.
- Over the full 9 years of available data (2017 to 2025), IGC Pharma, Inc.'s Gross Profit has grown by 183.6%.
- Historical annual values: Fiscal year 2025: $619.0 thousand | Fiscal year 2024: $733.0 thousand | Fiscal year 2023: $442.0 thousand | Fiscal year 2022: $194.0 thousand | Fiscal year 2021: $113.0 thousand | Fiscal year 2020: $115.0 thousand | Fiscal year 2019: $132.0 thousand | Fiscal year 2018: $82.0 thousand | Fiscal year 2017: $218.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: